在接受外周动脉干预的患者中进行抗血栓治疗
Mario Enrico Canonico1, Connie N Hess2, Eric A Secemsky3
1CPC Clinical Research, Aurora, CO, USA; Division of Cardiology, Department of Medicine, University of Colorado School of Medicine, Aurora, CO, USA.
双通道抑制 (DPI) 疗法,结合阿司匹林和低剂量里瓦洛克萨班,有效地减少下肢再血管化 (LER) 后外周动脉疾病 (PAD) 患者的不良心血管和四肢事件. 这种方法平衡了疗效和出血风险,支持其更广泛的临床采用.
科学领域:
- 血管外科 血管外科
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 患有外周动脉疾病 (PAD) 的患者接受下肢再血管化 (LER),面临心血管和四肢缺血事件的高风险.
- 抗血栓治疗对于预防血栓并发症至关重要,但必须平衡出血风险的增加.
- 双通道抑制 (DPI) 提出了一种降低这些风险的策略.
研究的目的:
- 评估双通道抑制 (DPI) 治疗在LER后PAD患者的疗效和安全性.
- 评估主要不良心血管和四肢相关事件的减少.
- 为了确定对重大出血事件的影响.
主要方法:
- 阿司匹林与低剂量里瓦罗克萨班 (双通道抑制) 结合给LER后的PAD患者.
- 监测了包括主要不良心血管和四肢相关事件在内的结果.
- 评估主要出血事件以评估安全性.
主要成果:
- DPI治疗显示,主要心血管和四肢相关不良事件的减少.
- 大型出血事件的发生率与标准疗法相比没有显著差异.
- 这些发现支持DPI在高风险患者群体中的有效性.
结论:
- 双通道抑制 (阿司匹林加上低剂量里瓦洛克萨班) 有效地减少LER后PAD患者的不良事件.
- 这种策略在预防缺血事件和管理出血风险之间提供了有利的平衡.
- 在LER后的PAD患者的常规实践中广泛实施DPI治疗是有必要的.
更多相关视频
13:48Reduction of Radiation Exposure during Endovascular Treatment of Peripheral Arterial Disease Combining Fiber Optic RealShape Technology and Intravascular Ultrasound
Published on: April 21, 2023
07:25Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia
Published on: September 22, 2020
相关概念视频
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Local Anesthetics: Clinical Application as Intravenous Regional Anesthesia
One of the advantages of...
